免疫細胞療法市場レポート：2031年までの動向、予測、競合分析

世界の免疫細胞療法市場の将来は、病院とがん研究機関市場に機会がありそうです。世界の免疫細胞療法市場は、2025年から2031年にかけてCAGR 22.4%の成長が見込まれています。この市場の主な促進要因は、高齢者人口の増加、がん罹患率の増加、細胞ベースの治療法開発の進行です。

• Lucintel社の予測では、治療法の種類別では、CAR T細胞療法が、新しいCAR T細胞療法の研究開発に対する各社の継続的な投資により、予測期間中最大のセグメントであり続けています。
• 最終用途産業カテゴリーでは、がんの発生件数の増加により世界中で入院件数が増加しているため、病院が引き続き最大セグメントとなります。
• 地域別では、北米は高度なヘルスケアインフラの存在と同地域における医療費の増加により、予測期間中も最大地域であり続けると思われます。

免疫細胞療法市場の戦略的成長機会

免疫細胞療法市場は、バイオテクノロジーの進歩、免疫メカニズムの理解の深まり、がんや自己免疫疾患の有病率の上昇を背景に、大きく成長する見込みです。研究の進展と臨床応用の拡大に伴い、様々な治療応用においていくつかの重要な機会が生まれつつあります。これらの機会は、革新的な治療の可能性を強調するだけでなく、個別化医療の重要性の高まりを強調しています。利害関係者はこれらの戦略的分野に焦点を当てることで、免疫細胞療法の進化する展望を活用し、アンメット・メディカル・ニーズに対応することができます。

• 血液悪性腫瘍白血病やリンパ腫を含む血液悪性腫瘍は、免疫細胞療法、特にCAR-T細胞療法の重要な応用分野です。最近の進歩により、複数のCAR-T製品が承認され、患者の転帰が大幅に改善されました。研究が進むにつれて、既存の治療法に耐性のあるものも含め、さまざまなタイプの血液がんを標的とした新しい治療法を開発する機会があります。さらに、CAR-T療法の安全性プロファイルを強化し、副作用を軽減することで、より個別化された治療オプションへの道を開き、この分野での市場浸透を拡大することができます。
• 固形がん：固形がんの治療は免疫細胞療法市場の新たな成長機会です。これまで免疫細胞療法は、腫瘍微小環境のために固形腫瘍を効果的に標的とすることが難しいという課題に直面してきました。しかし、免疫チェックポイント阻害薬と人工T細胞を組み込んだ併用療法などの革新的な戦略は、臨床試験で有望視されています。乳がん、肺がん、膵臓がんなど、特定の固形がん種に合わせた治療法の開発に注力することで、腫瘍学における重大なアンメットニーズに対応することができます。これらの治療法が進歩すれば、市場範囲を大幅に拡大し、患者の転帰を改善する可能性があります。
• 自己免疫疾患：免疫細胞療法は自己免疫疾患の治療薬としてますます研究が進んでおり、ユニークな成長機会をもたらしています。関節リウマチ、ループス、多発性硬化症などの疾患は、免疫反応を調節する治療法の恩恵を受ける可能性があります。研究開発では、疾患の進行を引き起こす特定の免疫細胞を標的とする治療法の開発に焦点が当てられており、従来の免疫抑制剤よりも効果的で安全な治療法を提供できる可能性があります。免疫制御に関する理解が進むにつれて、この分野における免疫細胞療法の応用は拡大し、自己免疫疾患の管理における革新的な解決策に対する重要なニーズに応えることが期待されます。
• 個別化医療：個別化医療と免疫細胞療法の融合は大きな成長の可能性を秘めています。個人の遺伝的・分子的プロファイルに基づいて治療をカスタマイズすることで、治療効果を高め、副作用を最小限に抑えることができます。コンパニオン診断薬は、特定の治療に適した候補者を特定する上でますます重要性を増しており、より正確で効果的な治療戦略を可能にしています。ヘルスケアにおける個別化アプローチの需要が高まり続ける中、利害関係者は、標的免疫細胞療法を開発し、コンパニオン診断ツールのためのパートナーシップを確立することにより、この傾向を利用し、最終的に患者の転帰と満足度を向上させることができます。
• 併用療法：免疫細胞療法と他の治療法との併用は、今後の成長が期待される分野です。免疫チェックポイント阻害剤、分子標的治療薬、放射線療法を免疫細胞療法に組み入れる戦略は、総合的な有効性を高め、様々ながんにおける耐性メカニズムを克服することができます。臨床試験では、このような併用療法の研究がますます進んでおり、相乗効果の可能性が示されています。併用療法に関する確固とした臨床エビデンスの開発に注力することで、利害関係者は市場での競争力を高めることができます。この戦略は、免疫細胞療法の治療応用を広げるだけでなく、複雑な疾患を抱える患者の多様なニーズに応えることにもなります。

免疫細胞療法市場は、血液悪性腫瘍、固形がん、自己免疫疾患、個別化医療、併用療法など、主要な応用分野にわたって数多くの戦略的成長機会を提供しています。利害関係者はこれらの分野に注力することで、患者の進化するニーズに対応するための製品提供を革新・拡大することができます。研究開発が進むにつれて、免疫細胞療法が治療環境を一変させ、患者の予後を改善する可能性がますます明らかになり、市場は今後数年間で大きく成長するものと思われます。

免疫細胞療法市場の促進要因・課題

免疫細胞療法市場は、技術の進歩、経済状況、規制の枠組みなどに起因する多くの市場促進要因・課題によって形成されています。主な促進要因としては、治療法開発における技術革新、がんや自己免疫疾患の有病率の上昇、研究開発への投資の増加などが挙げられます。しかし、高額な治療費、複雑な承認プロセス、代替療法との競合といった課題も市場力学に影響を与えています。これらの要因を理解することは、急速に発展するこの市場の複雑さを乗り切り、成長機会を活かそうとする利害関係者にとって極めて重要です。

免疫細胞療法市場を牽引している要因は以下の通りです：

• バイオテクノロジーの進歩：バイオテクノロジーの進歩：バイオテクノロジー、特に遺伝子編集と細胞工学の技術的進歩は免疫細胞療法市場の主要促進要因です。CRISPRやその他の遺伝子改変技術のような技術革新は、より効果的で的を絞った治療法の開発を促進しています。これらの進歩により、CAR-T細胞や、特定のがんや自己免疫疾患をより効果的に標的とするその他の免疫調整治療法の創製が可能になりました。研究者がこれらの技術を改良し続けることで、免疫細胞療法の安全性、有効性、拡張性が向上し、最終的には臨床現場での採用が進むことになります。
• がんと自己免疫疾患の増加：がんと自己免疫疾患の罹患率の増加は、免疫細胞療法市場の重要な促進要因です。がんの罹患率は世界的に上昇を続けており、自己免疫疾患は数百万人に影響を及ぼしているため、効果的な治療オプションが急務となっています。免疫細胞療法、特にCAR-T療法は、特定のがんの治療において目覚ましい成果を示しています。認知度が高まり、先進的な治療を求める患者が増えるにつれて、革新的な免疫細胞療法に対する需要は増加し、市場の成長をさらに促進すると予想されます。
• 研究開発投資の拡大：研究開発への投資は免疫細胞療法市場を牽引する極めて重要な要素です。政府、学術機関、非公開会社は、新しい治療法の研究や既存の治療法の改良に多額の資金を投入しています。このような研究開発への注力は、新規免疫細胞療法の発見を促進し、臨床試験への移行を加速しています。開発中の新規治療薬のパイプラインが充実していることから、アンメットメディカルニーズへの対応に研究者たちが邁進している現在、市場は継続的な成長を遂げる好位置にあります。
• 支持的な規制環境：免疫細胞療法市場の成長には、支援的な規制環境が不可欠です。バイオテクノロジーの急速な進歩に対応し、革新的な治療法の承認を迅速化するために、規制当局の枠組みへの適応はますます進んでいます。画期的な治療法に対するアクセラレーテッド・パスウェイなどのイニシアチブは、審査プロセスの合理化に役立ち、患者がより早く新しい治療にアクセスできるようにします。このような規制当局の積極的な取り組みは、技術革新を助長する環境を育み、免疫細胞療法開発への投資を促進します。
• 個別化医療への需要の高まり：個別化医療へのシフトは免疫細胞療法市場の重要な促進要因です。遺伝学的・分子生物学的特性を含む個々の患者プロファイルに基づいて治療をカスタマイズすることで、治療効果を高め、副作用を最小限に抑えることができます。コンパニオン診断薬の利用が進むにつれ、より正確な患者選択が可能になり、治療薬が最も適切な状況で使用されるようになります。ヘルスケア業界が個別化アプローチを採用し続けるにつれて、標的免疫細胞療法に対する需要は拡大し、市場機会はさらに拡大すると予想されます。

免疫細胞療法市場における課題は以下の通りです：

• 高い治療費：免疫細胞療法市場が直面する主な課題のひとつは、治療にかかるコストの高さです。免疫細胞療法の製造工程は複雑で資源集約的であるため、多額の費用が必要となり、患者の利用が制限される可能性があります。多くの治療法、特にCAR-T製品は、1回の治療につき数十万米ドルを超えることもあります。このような経済的負担は、ヘルスケアシステムや保険会社に課題をもたらし、治療アクセスの格差につながる可能性があります。こうしたコスト問題に対処することは、市場を拡大し、公平な患者アクセスを確保する上で極めて重要です。
• 複雑な規制当局の承認プロセス：規制当局の支援は強化されつつあるが、免疫細胞療法の承認プロセスは依然として複雑で長いです。開発者は厳格な臨床試験要件をクリアし、安全性と有効性の確固たる証拠を示さなければならないため、革新的な治療法の市場参入を遅らせる可能性があります。さらに、これらの治療法は進化しているため、規制当局との継続的な対話が必要となり、薬事申請が複雑になる可能性があります。こうした課題は投資を抑制し、技術革新のペースを遅らせ、免疫細胞療法市場全体の成長に影響を与える可能性があります。
• 代替療法との競合：免疫細胞療法市場は、従来の化学療法、標的療法、免疫療法などの代替治療法との大きな競合に直面しています。これらの代替療法は進化と改良を続けており、免疫細胞療法を採用する上での課題となっています。患者によっては、より長い実績を持つ確立された治療法を好む場合もあれば、新しい治療法を試すことをためらう場合もあります。免疫細胞療法を成功させるためには、利害関係者が免疫細胞療法の独自の長所と臨床上の利点を効果的に実証し、免疫細胞療法を最新の治療計画に欠かせないものとして位置づけなければなりません。

免疫細胞療法市場は、市場促進要因・課題が複雑に絡み合って影響を受けています。バイオテクノロジーの進歩、疾患罹患率の増加、競合環境が成長を促進する一方で、治療費の高騰、複雑な承認、代替療法との競合がハードルとなっています。利害関係者はこれらの力学をうまく操りながら、新たな機会を生かし、課題に効果的に対処し、臨床における免疫細胞療法の継続的な進歩を確保しなければなりません。

目次

第1章 エグゼクティブサマリー

第2章 世界の免疫細胞療法市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019-2024年）と予測（2025-2031年）
• 世界の免疫細胞療法市場の動向（2019-2024年）と予測（2025-2031年）
• 治療タイプ別：世界の免疫細胞療法市場
  • CAR T細胞療法
  • 樹状細胞療法
  • NK細胞療法
  • TIL療法
  • その他
• 適応症別：世界の免疫細胞療法市場
  • B細胞悪性腫瘍
  • 前立腺がん
  • 肝臓がん
  • 腎細胞がん
  • その他
• 最終用途産業別：世界の免疫細胞療法市場
  • 病院
  • がん研究所
  • その他

第4章 2019年から2031年までの市場動向と予測分析、地域別

• 地域別：世界の免疫細胞療法市場
• 北米の免疫細胞療法市場
• 欧州の免疫細胞療法市場
• アジア太平洋地域の免疫細胞療法市場
• その他地域免疫細胞療法市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 治療タイプ別：世界の免疫細胞療法市場の成長機会
  • 適応症別：世界の免疫細胞療法市場の成長機会
  • 最終用途産業別：世界の免疫細胞療法市場の成長機会
  • 地域別：世界の免疫細胞療法市場の成長機会
• 世界の免疫細胞療法市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の免疫細胞療法市場の能力拡大
  • 世界の免疫細胞療法市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Bristol-Myers Squibb Company
• Novartis
• Gilead Sciences
• F. Hoffmann-La Roche
• Merck
• GlaxoSmithKline
• AstraZeneca
• Pfizer
• Johnson & Johnson
• Celyad

The future of the global immune cell therapy market looks promising with opportunities in the hospitals and cancer institutes markets. The global immune cell therapy market is expected to grow with a CAGR of 22.4% from 2025 to 2031. The major drivers for this market are the increasing elderly population, the growing incidence of cancer, and the ongoing development of cell-based therapies.

• Lucintel forecasts that, within the therapy type category, CAR T cell therapy will remain the largest segment over the forecast period due to ongoing investment by players in R&D of new CAR T cell therapy.
• Within the end-use industry category, hospitals will remain the largest segment due to the growing occurrence of cancer has increased the number of hospitalizations across the globe.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of advanced healthcare infrastructure and rising healthcare expenditure in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Immune Cell Therapy Market

The immune cell therapy market is characterized by several emerging trends that are shaping its future. As advancements in technology and research continue, these trends highlight the evolving landscape of immune therapies. Understanding these trends is essential for stakeholders aiming to capitalize on growth opportunities and address emerging challenges.

• Increased Focus on Combination Therapies: There is a growing emphasis on combining immune cell therapies with other treatment modalities, such as checkpoint inhibitors, targeted therapies, and chemotherapy. This approach aims to enhance overall treatment efficacy and address resistance mechanisms. Combination therapies have shown promising results in preclinical and clinical studies, leading to improved patient outcomes, particularly in challenging cases like solid tumors. By leveraging the synergistic effects of different therapeutic agents, researchers are exploring innovative treatment protocols that could significantly expand the applications of immune cell therapies and provide more comprehensive cancer care.
• Advancements in Cell Engineering: Innovations in cell engineering are transforming immune cell therapies, allowing for the development of next-generation CAR-T cells and other modified immune cells. Techniques such as CRISPR gene editing and synthetic biology are being employed to enhance the specificity and efficacy of immune cells while reducing potential side effects. Researchers are focusing on creating "off-the-shelf" products that can be manufactured at scale, reducing the time and cost associated with personalized therapies. These advancements are expected to improve patient access to immune cell therapies and broaden their applications across various disease indications.
• Growing Interest in Solid Tumors: Historically, immune cell therapies have primarily targeted hematological malignancies, but there is increasing interest in applying these therapies to solid tumors. Researchers are exploring various strategies to overcome the unique challenges posed by the tumor microenvironment, such as tumor heterogeneity and immune suppression. New CAR-T constructs and other immune-modulating therapies are being developed specifically for solid tumors. Clinical trials are underway to assess their efficacy in treating cancers like breast, lung, and pancreatic cancers, marking a significant shift that could expand the market potential for immune cell therapies.
• Expansion of Regulatory Frameworks: Regulatory bodies across the globe are adapting to the rapid advancements in immune cell therapies, creating more streamlined approval processes. Initiatives aimed at expediting the review of innovative therapies are becoming more common, enabling faster access to critical treatments for patients. This trend is particularly evident in markets like the U.S. and China, where regulators are actively encouraging the development of advanced therapies through supportive policies and guidelines. As regulatory frameworks continue to evolve, they will foster innovation and provide a conducive environment for the growth of the immune cell therapy market.
• Rise of Personalized Medicine: The shift toward personalized medicine is becoming increasingly prominent in the immune cell therapy market. Tailoring therapies to individual patients based on genetic, epigenetic, and proteomic profiling allows for more effective and targeted treatments. This trend is driving the development of companion diagnostics to identify suitable candidates for specific immune cell therapies. By aligning treatment options with patient profiles, healthcare providers can enhance therapeutic efficacy and minimize adverse effects. The focus on personalized medicine reflects a broader movement within healthcare, emphasizing individualized treatment strategies to improve patient outcomes and satisfaction.

The immune cell therapy market is undergoing significant transformation, characterized by advancements across various regions and the emergence of key trends. With a growing focus on combination therapies, cell engineering innovations, and the expansion into solid tumors, the future of this market looks promising. Regulatory support and the emphasis on personalized medicine further enhance the landscape, allowing for improved patient outcomes and broader access to therapies. Stakeholders must remain attuned to these developments to navigate challenges effectively and seize opportunities in this dynamic and rapidly evolving market.

Recent Developments in the Immune Cell Therapy Market

The immune cell therapy market is experiencing rapid growth and innovation, driven by advancements in biotechnology and an increased understanding of the immune system role in combating diseases. Recent developments include breakthroughs in CAR-T cell therapies, improved methods for targeting solid tumors, enhancements in cell engineering, regulatory advancements, and the integration of personalized medicine approaches. These innovations not only expand treatment options but also enhance efficacy and patient outcomes. As the field evolves, these developments are setting the stage for a new era in cancer treatment and other immune-mediated diseases.

• Advancements in CAR-T Cell Therapies: Recent advancements in CAR-T cell therapies have significantly expanded their application beyond hematological malignancies to include solid tumors. Innovative CAR designs are being developed to improve T-cell persistence and targeting accuracy. Clinical trials have shown promising results, demonstrating the potential of these therapies to enhance patient outcomes. Companies are also focusing on refining manufacturing processes to reduce costs and improve accessibility. This progress is expected to lead to a wider range of CAR-T products entering the market, providing patients with more options for effective treatment.
• Targeting Solid Tumors: Historically, immune cell therapies have primarily been effective in treating blood cancers. However, there is growing focus on adapting these therapies to target solid tumors, which present unique challenges. Researchers are exploring new strategies, such as combination therapies that pair immune cell treatments with checkpoint inhibitors or other agents that can enhance immune response. Clinical trials are underway to test these approaches, and preliminary results indicate potential for effective treatment options in challenging cancer types like breast, lung, and pancreatic cancers.
• Innovations in Cell Engineering: Innovations in cell engineering are paving the way for next-generation immune cell therapies. Techniques like CRISPR gene editing are being utilized to create enhanced T-cell products with improved specificity and reduced side effects. This includes developing "off-the-shelf" therapies that can be manufactured at scale, making treatments more accessible and cost-effective. The ability to modify immune cells more precisely allows researchers to create tailored therapies that are better suited to individual patient needs, potentially increasing the effectiveness of treatments across a broader range of diseases.
• Evolving Regulatory Landscape: The regulatory landscape for immune cell therapies is evolving to keep pace with rapid advancements in the field. Regulatory agencies in key markets, such as the U.S. and Europe, are streamlining approval processes to expedite the entry of innovative therapies into the market. Initiatives like adaptive trial designs and expedited review pathways are becoming more common, allowing for faster access to life-saving treatments. This supportive regulatory environment is encouraging investment and research, fostering a climate conducive to the development of groundbreaking therapies.
• Integration of Personalized Medicine: The trend toward personalized medicine is gaining traction in the immune cell therapy market. Tailoring therapies based on individual genetic profiles and tumor characteristics is enhancing treatment efficacy. Companion diagnostics are being developed to identify patients who are most likely to benefit from specific immune cell therapies, ensuring more precise treatment strategies. This integration not only improves patient outcomes but also aligns with the broader shift in healthcare toward individualized treatment approaches. As personalized medicine becomes more prevalent, it will further shape the future of immune cell therapies.

The immune cell therapy market is witnessing significant developments that are reshaping treatment paradigms for cancer and immune-mediated diseases. Advancements in CAR-T therapies, the ability to target solid tumors, innovations in cell engineering, a supportive regulatory landscape, and the integration of personalized medicine are driving growth and improving patient outcomes. These developments highlight the potential for immune cell therapies to revolutionize treatment options, offering hope to patients with previously difficult-to-treat conditions. As research and innovation continue, the future of this market looks promising, with the potential for new breakthroughs on the horizon.

Strategic Growth Opportunities for Immune Cell Therapy Market

The immune cell therapy market is poised for significant growth, driven by advances in biotechnology, an increasing understanding of immune mechanisms, and the rising prevalence of cancer and autoimmune diseases. As research progresses and clinical applications expand, several key opportunities are emerging across various therapeutic applications. These opportunities not only highlight the potential for innovative treatments but also emphasize the growing importance of personalized medicine. By focusing on these strategic areas, stakeholders can capitalize on the evolving landscape of immune cell therapies and address unmet medical needs.

• Hematological Malignancies: Hematological malignancies, including leukemia and lymphoma, represent a key application area for immune cell therapies, particularly CAR-T cell therapies. Recent advancements have led to the successful approval of multiple CAR-T products, significantly improving patient outcomes. As research continues, there is an opportunity to develop new therapies targeting different types of blood cancers, including those that are resistant to existing treatments. Furthermore, enhancing the safety profiles and reducing side effects of CAR-T therapies can expand their use, paving the way for more personalized treatment options and increasing market penetration in this area.
• Solid Tumors: The treatment of solid tumors is an emerging growth opportunity in the immune cell therapy market. Historically, immune cell therapies have faced challenges in effectively targeting solid tumors due to the tumor microenvironment. However, innovative strategies, such as combination therapies that incorporate immune checkpoint inhibitors and engineered T-cells, are showing promise in clinical trials. Focusing on developing therapies tailored for specific solid tumor types, including breast, lung, and pancreatic cancers, can address significant unmet needs in oncology. As these therapies advance, they have the potential to substantially broaden the market scope and improve patient outcomes.
• Autoimmune Diseases: Immune cell therapies are increasingly being explored for treating autoimmune diseases, presenting a unique growth opportunity. Conditions like rheumatoid arthritis, lupus, and multiple sclerosis could benefit from therapies that modulate the immune response. Research is focusing on developing therapies that target specific immune cells responsible for disease progression, potentially offering more effective and safer treatment options than traditional immunosuppressive drugs. As the understanding of immune regulation improves, the application of immune cell therapies in this area is expected to expand, meeting a critical need for innovative solutions in the management of autoimmune conditions.
• Personalized Medicine: The integration of personalized medicine into immune cell therapy offers significant growth potential. Tailoring therapies based on individual genetic and molecular profiles enhances treatment efficacy and minimizes adverse effects. Companion diagnostics are becoming increasingly important in identifying suitable candidates for specific therapies, allowing for more precise and effective treatment strategies. As the demand for personalized approaches in healthcare continues to rise, stakeholders can capitalize on this trend by developing targeted immune cell therapies and establishing partnerships for companion diagnostic tools, ultimately improving patient outcomes and satisfaction.
• Combination Therapies: Combining immune cell therapies with other treatment modalities is a promising area for growth. Strategies that incorporate immune checkpoint inhibitors, targeted therapies, or radiation with immune cell therapies can enhance overall efficacy and overcome resistance mechanisms in various cancers. Clinical trials are increasingly exploring these combination approaches, demonstrating potential synergistic effects. By focusing on developing robust clinical evidence for combination therapies, stakeholders can position themselves competitively in the market. This strategy not only broadens the therapeutic applications of immune cell therapies but also addresses the diverse needs of patients with complex diseases.

The immune cell therapy market presents numerous strategic growth opportunities across key applications, including hematological malignancies, solid tumors, autoimmune diseases, personalized medicine, and combination therapies. By focusing on these areas, stakeholders can innovate and expand their offerings to meet the evolving needs of patients. As research and development continue to advance, the potential for immune cell therapies to transform treatment landscapes and improve patient outcomes becomes increasingly evident, positioning the market for substantial growth in the coming years.

Immune Cell Therapy Market Driver and Challenges

The immune cell therapy market is shaped by a multitude of drivers and challenges that stem from technological advancements, economic conditions, and regulatory frameworks. Key drivers include innovations in therapy development, a rising prevalence of cancers and autoimmune diseases, and increasing investments in research and development. However, challenges such as high treatment costs, complex regulatory approval processes, and competition from alternative therapies also impact market dynamics. Understanding these factors is crucial for stakeholders seeking to navigate the complexities of this rapidly evolving market and capitalize on growth opportunities.

The factors responsible for driving the immune cell therapy market include:

• Advancements in Biotechnology: Technological advancements in biotechnology, particularly in gene editing and cell engineering, are major drivers of the immune cell therapy market. Innovations like CRISPR and other genetic modification techniques have facilitated the development of more effective and targeted therapies. These advancements enable the creation of CAR-T cells and other immune-modulating treatments that can better target specific cancers or autoimmune diseases. As researchers continue to refine these technologies, they enhance the safety, efficacy, and scalability of immune cell therapies, ultimately driving greater adoption in clinical settings.
• Increasing Incidence of Cancer and Autoimmune Diseases: The rising prevalence of cancer and autoimmune diseases is a significant driver for the immune cell therapy market. With cancer rates continuing to climb globally and autoimmune disorders affecting millions, there is an urgent need for effective treatment options. Immune cell therapies, especially CAR-T therapies, have shown remarkable results in treating certain cancers. As awareness grows and more patients seek advanced therapies, the demand for innovative immune cell treatments is expected to increase, further propelling market growth.
• Growing Investment in Research and Development: Investments in research and development are pivotal for driving the immune cell therapy market. Governments, academic institutions, and private companies are allocating substantial funds to explore new therapeutic approaches and improve existing ones. This focus on R&D facilitates the discovery of novel immune cell therapies and accelerates their progression through clinical trials. With a robust pipeline of new therapies in development, the market is well-positioned for continued growth as researchers strive to address unmet medical needs.
• Supportive Regulatory Environment: A supportive regulatory environment is essential for the growth of the immune cell therapy market. Regulatory bodies are increasingly adapting their frameworks to accommodate the rapid advancements in biotechnology and expedite the approval of innovative therapies. Initiatives such as accelerated pathways for breakthrough therapies help streamline the review process, allowing patients faster access to new treatments. This proactive approach by regulatory agencies fosters an environment conducive to innovation and encourages investment in the development of immune cell therapies.
• Rising Demand for Personalized Medicine: The shift towards personalized medicine is a significant driver in the immune cell therapy market. Tailoring therapies based on individual patient profiles, including genetic and molecular characteristics, enhances treatment efficacy and minimizes side effects. The increasing use of companion diagnostics allows for more precise patient selection, ensuring that therapies are used in the most appropriate contexts. As the healthcare industry continues to embrace personalized approaches, the demand for targeted immune cell therapies is expected to grow, further expanding market opportunities.

Challenges in the immune cell therapy market are:

• High Treatment Costs: One of the primary challenges facing the immune cell therapy market is the high cost associated with these treatments. The manufacturing processes for immune cell therapies are complex and resource-intensive, leading to significant expenses that can limit accessibility for patients. Many therapies, especially CAR-T products, can exceed hundreds of thousands of dollars per treatment. This financial burden poses challenges for healthcare systems and insurers, potentially leading to disparities in treatment access. Addressing these cost issues will be critical for expanding the market and ensuring equitable patient access.
• Complex Regulatory Approval Processes: While regulatory bodies are becoming more supportive, the approval processes for immune cell therapies remain complex and lengthy. Developers must navigate rigorous clinical trial requirements and demonstrate robust evidence of safety and efficacy, which can delay the market entry of innovative therapies. Additionally, the evolving nature of these therapies may complicate regulatory submissions, requiring ongoing dialogue with agencies. These challenges can deter investment and slow the pace of innovation, impacting the overall growth of the immune cell therapy market.
• Competition from Alternative Therapies: The immune cell therapy market faces significant competition from alternative treatment modalities, such as traditional chemotherapy, targeted therapies, and immunotherapies. As these alternatives continue to evolve and improve, they pose challenges to the adoption of immune cell therapies. Some patients may prefer established treatments with a longer track record, while others may be hesitant to try newer, less understood options. For immune cell therapies to succeed, stakeholders must effectively demonstrate their unique advantages and clinical benefits, positioning them as essential components of modern treatment regimens.

The immune cell therapy market is influenced by a complex interplay of drivers and challenges. Advancements in biotechnology, increasing disease prevalence, and a supportive regulatory environment foster growth, while high treatment costs, complex approvals, and competition from alternative therapies present hurdles. Stakeholders must navigate these dynamics to capitalize on emerging opportunities and address challenges effectively, ensuring the continued advancement of immune cell therapies in clinical practice.

List of Immune Cell Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies immune cell therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the immune cell therapy companies profiled in this report include-

• Bristol-Myers Squibb Company
• Novartis
• Gilead Sciences
• F. Hoffmann-La Roche
• Merck
• GlaxoSmithKline
• AstraZeneca
• Pfizer
• Johnson & Johnson
• Celyad

Immune Cell Therapy by Segment

The study includes a forecast for the global immune cell therapy market by therapy type, indication, end-use industry, and region.

Immune Cell Therapy Market by Therapy Type [Analysis by Value from 2019 to 2031]:

• CAR T Cell Therapy
• Dendritic Cell Therapy
• NK Cell Therapy
• TIL Therapy
• Others

Immune Cell Therapy Market by Indication [Analysis by Value from 2019 to 2031]:

• B-Cell Malignancies
• Prostate Cancer
• Liver Cancer
• Renal Cell Carcinoma
• Others

Immune Cell Therapy Market by End-Use Industry [Analysis by Value from 2019 to 2031]:

• Hospitals
• Cancer Institutes
• Others

Immune Cell Therapy Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Immune Cell Therapy Market

The immune cell therapy market is rapidly evolving, driven by significant advancements in biotechnology and a growing understanding of the immune system's role in disease treatment. Innovative therapies, particularly CAR-T cell therapies and other immune-modulating treatments, are gaining traction in the United States, China, Germany, India, and Japan. These developments are facilitated by increasing investments in research and clinical trials, regulatory support, and a rising incidence of cancers and autoimmune diseases. As the global focus on personalized medicine intensifies, the immune cell therapy market is poised for substantial growth and transformation in the coming years.

• United States: In the United States, the immune cell therapy market has seen remarkable advancements, particularly in CAR-T cell therapies. Companies like Gilead Sciences and Bristol-Myers Squibb continue to lead the way with innovative treatments for hematologic malignancies. Recent approvals by the FDA for new CAR-T products have expanded treatment options for patients with refractory cancers. Additionally, ongoing clinical trials are exploring the use of immune cell therapies for solid tumors and autoimmune diseases. The U.S. also benefits from a robust investment environment, with significant funding flowing into research and development, driving innovation and accessibility of these therapies.
• China: China is rapidly becoming a key player in the immune cell therapy market, with increasing investments from both public and private sectors. The country has seen a surge in the development of CAR-T therapies, with domestic companies like JW Therapeutics making significant strides in clinical trials and commercialization. Regulatory bodies have streamlined approval processes, facilitating faster access to innovative therapies. Collaborations between Chinese biotech firms and international companies are also enhancing the development of next-generation immune therapies. This growing ecosystem is expected to bolster China's position as a global leader in immune cell therapy research and commercialization.
• Germany: Germany is at the forefront of immune cell therapy advancements in Europe, focusing on both CAR-T therapies and innovative research in T-cell engineering. Leading institutions and biotech firms are conducting extensive clinical trials aimed at expanding the application of immune cell therapies in treating various cancers. The German government is actively supporting research initiatives through funding and regulatory frameworks that encourage innovation. Additionally, collaborations between academia and industry are driving breakthroughs in personalized medicine. Germany's strong healthcare infrastructure further supports the integration and accessibility of these therapies, positioning it as a significant market in Europe.
• India: India's immune cell therapy market is emerging rapidly, driven by increasing investment in biotechnology and healthcare infrastructure. While still in the nascent stages compared to Western markets, India is witnessing a rise in clinical trials focused on CAR-T therapies and other immune-based treatments. Local biotech companies are collaborating with international firms to enhance research capabilities and bring innovative therapies to market. Regulatory bodies are beginning to streamline approval processes, which will facilitate quicker access to these therapies. With a growing patient population and rising awareness of advanced treatments, India is poised for significant growth in the immune cell therapy sector.
• Japan: Japan is making notable progress in the immune cell therapy market, particularly in CAR-T cell therapies and regenerative medicine. The Japanese government has implemented supportive regulatory frameworks that encourage the development and commercialization of innovative therapies. Leading pharmaceutical companies, in collaboration with research institutions, are conducting clinical trials to explore new immune cell therapies for cancer and other diseases. The growing focus on personalized medicine is also driving interest in immune cell therapies, with a commitment to integrating these innovations into standard treatment protocols. Japan's strong healthcare system and technological capabilities position it as a key market in Asia.

Features of the Global Immune Cell Therapy Market

Market Size Estimates: Immune cell therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Immune cell therapy market size by therapy type, indication, end-use industry, and region in terms of value ($B).

Regional Analysis: Immune cell therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy types, indications, end-use industries, and regions for the immune cell therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the immune cell therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the immune cell therapy market by therapy type (CAR T cell therapy, dendritic cell therapy, NK cell therapy, TIL therapy, and others), indication (B-cell malignancies, prostate cancer, liver cancer, renal cell carcinoma, and others), end-use industry (hospitals, cancer institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Immune Cell Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Immune Cell Therapy Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Immune Cell Therapy Market by Therapy Type
  • 3.3.1: CAR T Cell Therapy
  • 3.3.2: Dendritic Cell Therapy
  • 3.3.3: NK Cell Therapy
  • 3.3.4: TIL Therapy
  • 3.3.5: Others
• 3.4: Global Immune Cell Therapy Market by Indication
  • 3.4.1: B-Cell Malignancies
  • 3.4.2: Prostate Cancer
  • 3.4.3: Liver Cancer
  • 3.4.4: Renal Cell Carcinoma
  • 3.4.5: Others
• 3.5: Global Immune Cell Therapy Market by End-Use Industry
  • 3.5.1: Hospitals
  • 3.5.2: Cancer Institutes
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Immune Cell Therapy Market by Region
• 4.2: North American Immune Cell Therapy Market
  • 4.2.1: North American Market by Therapy Type: CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, and Others
  • 4.2.2: North American Market by End-Use Industry: Hospitals, Cancer Institutes, and Others
• 4.3: European Immune Cell Therapy Market
  • 4.3.1: European Market by Therapy Type: CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, and Others
  • 4.3.2: European Market by End-Use Industry: Hospitals, Cancer Institutes, and Others
• 4.4: APAC Immune Cell Therapy Market
  • 4.4.1: APAC Market by Therapy Type: CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, and Others
  • 4.4.2: APAC Market by End-Use Industry: Hospitals, Cancer Institutes, and Others
• 4.5: ROW Immune Cell Therapy Market
  • 4.5.1: ROW Market by Therapy Type: CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, and Others
  • 4.5.2: ROW Market by End-Use Industry: Hospitals, Cancer Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Immune Cell Therapy Market by Therapy Type
  • 6.1.2: Growth Opportunities for the Global Immune Cell Therapy Market by Indication
  • 6.1.3: Growth Opportunities for the Global Immune Cell Therapy Market by End-Use Industry
  • 6.1.4: Growth Opportunities for the Global Immune Cell Therapy Market by Region
• 6.2: Emerging Trends in the Global Immune Cell Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Immune Cell Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Immune Cell Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Bristol-Myers Squibb Company
• 7.2: Novartis
• 7.3: Gilead Sciences
• 7.4: F. Hoffmann-La Roche
• 7.5: Merck
• 7.6: GlaxoSmithKline
• 7.7: AstraZeneca
• 7.8: Pfizer
• 7.9: Johnson & Johnson
• 7.10: Celyad